A Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) in India (MK-7962-037)

Inclusion Criteria: The main inclusion criteria include but are not limited to the following: * Has documented historical diagnostic right heart catheterization (RHC), with the diagnosis of pulmonary arterial hypertension (PAH), also known as Group 1 pulmonary hypertension (PH), in any of the following subtypes: Idiopathic PAH, Heritable PAH, Drug/toxin-induced PAH, PAH associated with connective tissue disease, and PAH associated with simple, congenital systemic-to-pulmonary shunts at least 1 year following repair * Has been on stable doses of PAH background therapies and diuretics (if applicable) * Has symptomatic PAH classified as World Health Organization (WHO) Functional Classification (FC) II or III Exclusion Criteria: The main exclusion criteria include but are not limited to the following: * Has a diagnosis of Groups 2, 3, 4, or 5 PH * Has a diagnosis of the following PAH (Group 1 PH) subtypes: human immunodeficiency virus (HIV)-associated PAH, PAH associated with portal hypertension, schistosomiasis-associated PAH, PAH diagnosed with pulmonary veno occlusive disease (PVOD) or pulmonary capillary hemangiomatosis (PCH) * Has uncontrolled systemic hypertension * Has a history of full or partial pneumonectomy * Has untreated more than mild obstructive sleep apnea * Has known history of portal hypertension or chronic liver disease, including hepatitis B and/or hepatitis C * Has a history of restrictive, constrictive, or congestive cardiomyopathy * Has significant mitral regurgitation or aortic regurgitation valvular disease, mitral stenosis, and more than mild aortic valve stenosis * Has known malignancy that is progressing or has required active treatment within the past 5 years